Symbols / BTTX
BTTX Chart
About
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis ,and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 5.45K |
| Enterprise Value | 7.71M | Income | -31.57M | Sales | — |
| Book/sh | -0.24 | Cash/sh | 0.14 | Dividend Yield | — |
| Payout | 0.00% | Employees | 54 | IPO | — |
| P/E | — | Forward P/E | -0.00 | PEG | — |
| P/S | — | P/B | -0.00 | P/C | — |
| EV/EBITDA | -0.26 | EV/Sales | — | Quick Ratio | 0.52 |
| Current Ratio | 0.57 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.10 | EPS next Y | -1.00 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2023-11-09 07:00 | ROA | -95.05% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 54.52M |
| Shs Float | 30.54M | Short Float | 6.21% | Short Ratio | 0.94 |
| Short Interest | — | 52W High | 0.00 | 52W Low | 0.00 |
| Beta | -43.86 | Avg Volume | 13.37K | Volume | 500.00 |
| Target Price | — | Recom | None | Prev Close | $0.00 |
| Price | $0.00 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-5.14
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-08-10 | main | Lake Street | Buy → Buy | $3 |
| 2023-08-10 | reit | Chardan Capital | Buy → Buy | $9 |
| 2023-04-14 | main | Lake Street | — → Buy | $5 |
| 2023-03-31 | main | Chardan Capital | — → Buy | $9 |
| 2022-11-15 | main | Chardan Capital | — → Buy | $14 |
| 2022-07-29 | main | Chardan Capital | — → Buy | $17 |
| 2022-03-16 | main | Chardan Capital | — → Buy | $18 |
| 2021-11-24 | init | Chardan Capital | — → Buy | $17 |
| 2021-11-10 | init | Cowen & Co. | — → Outperform | — |
- BTTX Stock Price and Chart — OTC:BTTX - TradingView Wed, 20 Mar 2024 07
- Better Therapeutics Shutters Operations, Terminates Employees, NASDAQ Delisting - HIT Consultant hu, 14 Mar 2024 07
- Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq - Business Wire hu, 14 Mar 2024 07
- Orchard (ORTX) Up 97% on $478M Acquisition Deal With Kyowa Kirin - Nasdaq Fri, 06 Oct 2023 07
- Better Therapeutics announces $6.5M private placement - MassDevice hu, 06 Apr 2023 07
- Crinetics (CRNX) Stock Surges 70% in a Month: Here's Why - Yahoo Finance hu, 28 Sep 2023 07
- 3 Penny Stocks That Have Huge Catalysts Ahead - InvestorPlace Mon, 27 Jun 2022 07
- Thinking about buying stock in Better Therapeutics, Surface Onco - GuruFocus Wed, 08 Jun 2022 07
- FDA grants breakthrough status to digital therapy for liver condition - Investing.com Nigeria ue, 20 Feb 2024 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | -36.82K |
| TaxRateForCalcs | 0.21 | 0.00 |
| NormalizedEBITDA | -35.53M | -28.94M |
| TotalUnusualItems | 0.00 | -9.74M |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -9.74M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -39.76M | -40.34M |
| ReconciledDepreciation | 2.73M | 1.62M |
| EBITDA | -35.53M | -38.68M |
| EBIT | -38.26M | -40.30M |
| NetInterestIncome | -1.49M | -185.00K |
| InterestExpense | 1.49M | 185.00K |
| NormalizedIncome | -39.76M | -30.63M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -39.76M | -40.34M |
| TotalExpenses | 38.26M | 30.56M |
| TotalOperatingIncomeAsReported | -38.26M | -30.56M |
| DilutedAverageShares | 23.56M | 12.98M |
| BasicAverageShares | 23.56M | 12.98M |
| DilutedEPS | -1.69 | -3.11 |
| BasicEPS | -1.69 | -3.11 |
| DilutedNIAvailtoComStockholders | -39.76M | -40.34M |
| NetIncomeCommonStockholders | -39.76M | -40.34M |
| NetIncome | -39.76M | -40.34M |
| NetIncomeIncludingNoncontrollingInterests | -39.76M | -40.34M |
| NetIncomeContinuousOperations | -39.76M | -40.34M |
| TaxProvision | 7.00K | -153.00K |
| PretaxIncome | -39.75M | -40.49M |
| OtherIncomeExpense | -9.74M | |
| SpecialIncomeCharges | 0.00 | 647.00K |
| OtherSpecialCharges | -647.00K | |
| GainOnSaleOfSecurity | -10.39M | |
| NetNonOperatingInterestIncomeExpense | -1.49M | -185.00K |
| InterestExpenseNonOperating | 1.49M | 185.00K |
| OperatingIncome | -38.26M | -30.56M |
| OperatingExpense | 38.26M | 30.56M |
| ResearchAndDevelopment | 16.44M | 19.44M |
| SellingGeneralAndAdministration | 21.82M | 11.12M |
| SellingAndMarketingExpense | 6.98M | 2.34M |
| GeneralAndAdministrativeExpense | 14.84M | 8.79M |
| OtherGandA | 14.84M | 8.79M |
| TotalRevenue | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 |
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| OrdinarySharesNumber | 23.85M | 23.60M |
| ShareIssued | 23.85M | 23.60M |
| TotalDebt | 14.88M | 9.51M |
| TangibleBookValue | -4.79M | 31.64M |
| InvestedCapital | 13.98M | 46.23M |
| WorkingCapital | 4.95M | 40.52M |
| NetTangibleAssets | -4.79M | 31.64M |
| CommonStockEquity | -899.00K | 36.72M |
| TotalCapitalization | 9.45M | 46.23M |
| TotalEquityGrossMinorityInterest | -899.00K | 36.72M |
| StockholdersEquity | -899.00K | 36.72M |
| RetainedEarnings | -111.50M | -71.74M |
| AdditionalPaidInCapital | 110.60M | 108.46M |
| CapitalStock | 2.00K | 2.00K |
| CommonStock | 2.00K | 2.00K |
| TotalLiabilitiesNetMinorityInterest | 23.84M | 14.24M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 10.35M | 9.51M |
| NonCurrentDeferredLiabilities | 0.00 | |
| NonCurrentDeferredTaxesLiabilities | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 10.35M | 9.51M |
| LongTermDebt | 10.35M | 9.51M |
| CurrentLiabilities | 13.49M | 4.73M |
| CurrentDebtAndCapitalLeaseObligation | 4.53M | |
| CurrentDebt | 4.53M | |
| PayablesAndAccruedExpenses | 8.96M | 4.73M |
| CurrentAccruedExpenses | 5.93M | 3.21M |
| InterestPayable | 168.00K | 77.00K |
| Payables | 3.04M | 1.52M |
| AccountsPayable | 3.04M | 1.52M |
| TotalAssets | 22.94M | 50.96M |
| TotalNonCurrentAssets | 4.50M | 5.71M |
| OtherNonCurrentAssets | 488.00K | 548.00K |
| GoodwillAndOtherIntangibleAssets | 3.89M | 5.08M |
| OtherIntangibleAssets | 3.89M | 5.08M |
| NetPPE | 121.00K | 82.00K |
| AccumulatedDepreciation | -57.00K | -228.00K |
| GrossPPE | 178.00K | 310.00K |
| MachineryFurnitureEquipment | 178.00K | 310.00K |
| CurrentAssets | 18.45M | 45.25M |
| OtherCurrentAssets | 210.00K | 276.00K |
| PrepaidAssets | 2.50M | 4.41M |
| CashCashEquivalentsAndShortTermInvestments | 15.74M | 40.57M |
| CashAndCashEquivalents | 15.74M | 40.57M |
| CashFinancial | 40.57M |
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| FreeCashFlow | -30.11M | -31.89M |
| IssuanceOfDebt | 5.00M | 28.68M |
| CapitalExpenditure | -1.18M | -1.07M |
| InterestPaidSupplementalData | 1.32M | 85.00K |
| EndCashPosition | 15.74M | 40.57M |
| BeginningCashPosition | 40.57M | 123.00K |
| ChangesInCash | -24.83M | 40.44M |
| FinancingCashFlow | 5.28M | 72.33M |
| CashFlowFromContinuingFinancingActivities | 5.28M | 72.33M |
| NetOtherFinancingCharges | -15.39M | |
| ProceedsFromStockOptionExercised | 284.00K | 59.05M |
| NetIssuancePaymentsOfDebt | 5.00M | 28.68M |
| NetLongTermDebtIssuance | 5.00M | 28.68M |
| LongTermDebtIssuance | 5.00M | 28.68M |
| InvestingCashFlow | -1.18M | -1.07M |
| CashFlowFromContinuingInvestingActivities | -1.18M | -1.07M |
| NetIntangiblesPurchaseAndSale | -1.02M | |
| PurchaseOfIntangibles | -1.02M | |
| NetPPEPurchaseAndSale | -106.00K | -55.00K |
| PurchaseOfPPE | -106.00K | -55.00K |
| CapitalExpenditureReported | -1.07M | -1.02M |
| OperatingCashFlow | -28.93M | -30.82M |
| CashFlowFromContinuingOperatingActivities | -28.93M | -30.82M |
| ChangeInWorkingCapital | 6.27M | -2.34M |
| ChangeInPayablesAndAccruedExpense | 4.23M | 2.27M |
| ChangeInAccruedExpense | 2.72M | 1.26M |
| ChangeInPayable | 1.51M | 1.01M |
| ChangeInAccountPayable | 1.51M | 1.01M |
| ChangeInPrepaidAssets | 2.04M | -4.61M |
| OtherNonCashItems | 9.74M | |
| StockBasedCompensation | 1.82M | 646.00K |
| AssetImpairmentCharge | 9.00K | 0.00 |
| DeferredTax | 0.00 | -152.00K |
| DeferredIncomeTax | 0.00 | -152.00K |
| DepreciationAmortizationDepletion | 2.73M | 1.62M |
| DepreciationAndAmortization | 2.73M | 1.62M |
| OperatingGainsLosses | -647.00K | |
| NetIncomeFromContinuingOperations | -39.76M | -40.34M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for BTTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|